Calculating of Correlations Between ADR, PDR, MAP

March 1, 2023 updated by: Ivana Mikoviny Kajzrlikova, MD, PhD, Hospital Frydek-Mistek
The aim of our study is to compare MAP (mean adenoma per colonoscopy) with ADR (adenoma detection rate) and PDR (polyp detection rate) of all colonoscopists in our department

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

ADR (adenoma detection rate) is generally accepted quality indicator. For possible gaming with ADR other indicators are needed. MAP (mean adenoma per colonoscopy) reflects the quality of examination of entire colon and is considered to be the most objective quality indicator. The aim of our study is to compare MAP with ADR and PDR (polyp detection rate) of all colonoscopists in our department.

We want to retrospectively assess the quality indicators of all colonoscopies from January 2013 to December 2017. We want to calculate ADR, PDR and MAP of all our endoscopists for all colonoscopies in patients over 50 years of age excluding therapeutic, IBD, management of complications and sigmoidoscopies (screening, surveillance, diagnostic) and separately only for screening colonoscopies. Correlations between MAP/ADR and MAP/PDR will be performed using Pearson´s correlation coefficient.

Study Type

Observational

Enrollment (Actual)

6925

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Czechia
      • Frýdek-Místek, Czechia
        • Hospital Frydek-Mistek

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

people over 50 years of age coming for colonoscopic examination

Description

Inclusion Criteria:

  • people over 50 years of age coming for colonoscopic examination (screening, surveillance, diagnostic)

Exclusion Criteria:

  • age under 50 years
  • indication for colonoscopy: therapeutic, IBD, management of complications and sigmoidoscopies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients after colonoscopy over 50 years
All colonoscopies in patients over 50 years of age (screening, surveillance, diagnostic) excluding therapeutic, IBD, management of complications and sigmoidoscopies
Device: Colonoscopy
Endoscopic examination of large bowel

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
correlation between MAP and ADR for all and screening colonoscopies
Time Frame: january 2013 - december 2017
Pearson´s correlation coefficient
january 2013 - december 2017
correlation between MAP and PDR for all and screening colonoscopies
Time Frame: january 2013 - december 2017
Pearson´s correlation coefficient
january 2013 - december 2017
correlation between ADR and PDR for all and screening colonoscopies
Time Frame: january 2013 - december 2017
Pearson´s correlation coefficient
january 2013 - december 2017

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital Frydek-Mistek

Investigators

  • Principal Investigator: Ivana Mikoviny Kajzrlikova, doctor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2013

Primary Completion (Actual)

December 1, 2017

Study Completion (Actual)

December 1, 2017

Study Registration Dates

First Submitted

October 26, 2018

First Submitted That Met QC Criteria

October 26, 2018

First Posted (Actual)

October 29, 2018

Study Record Updates

Last Update Posted (Actual)

March 2, 2023

Last Update Submitted That Met QC Criteria

March 1, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MAP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

ADR, PDR, MAP of all endoscopists in our unit for both all and screening colonoscopies

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Colon Neoplasm

Clinical Trials on Colonoscopy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe